Long-acting HIV prevention study for healthy adults
Part of Immune system & allergy, Infections clinical trials.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Be in generally good health
- Weigh at least 110 lbs (men) or 99 lbs (women)
- Have a body mass index (BMI) between 18.5 and 32 (unless in a specific group)
- Be willing to use effective contraception if you can become pregnant
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study tests an experimental medication in healthy volunteers to see how it is processed by the body and whether it is safe. You may not receive direct benefit, but your participation helps find better treatments for people with HIV.
This study tests a new oral drug to see if it is safe and how the body processes it. It is for healthy adults without HIV, and results will help determine if the drug could be used for HIV prevention in the future.
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.